drugset / Trial / NCT00481520

Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

NCT00481520

Phase 2 Completed 72 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupQuadruple-blind

Summary

The primary purpose of the study is to assess whether SAM-531, an investigational drug, is safe and well tolerated, compared with placebo (a medically inactive substance), in subjects with mild to moderate Alzheimer's disease.

Timeline

Start
2007-06
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CERLAPIRDINE Small molecule

Indications